On September 16, Tianmei bio held the "mid term coordination meeting for listing in the United States" at its headquarters in Xi'an. Relevant intermediaries, such as us new bridge securities (NSC), US Crohn law group (tclg), US Tengshi global capital (AGA) and Beijing Qianzhong law firm, gathered in Xi'an to participate in the meeting.

During the meeting, we evaluated, summarized and confirmed the "due diligence of American securities companies, American lawyers, on-site audit of American accountants and due diligence of Chinese lawyers". The meeting held that the basic work related to listing in the United States has been completed, and the compilation of Tianmei biological F1 registration documents will be accelerated in the next stage. All institutions will actively cooperate and work together to speed up the compilation of F1 documents, and submit F1 registration documents to the securities and Exchange Commission (SEC) and the U.S. financial regulatory agency (FINRA) for subsequent approval as soon as possible after the completion of the compilation.

This meeting is of great significance for Tianmei bio's listing in the United States, marking a new stage for Tianmei bio's listing in the United States. The company will coordinate all resources, actively promote the progress of listing, and strive for the company's early landing on NASDAQ.